Sorafenib after resection improves the outcome of BCLC stage C hepatocellular Carcinoma

World Journal of Gastroenterology

Volumn 22, Issue 15, 2016, Pages 4034-4040

  Li, Jiang ^a   Hou, Yu ^a   Cai, Xiao Bei ^a   Liu, Bin ^a  

^a KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

Hepatic resection; Hepatocellular Carcinoma; Recurrence; Sorafenib; Survival

Indexed keywords

ALPHA FETOPROTEIN; SORAFENIB; VIRUS DNA; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR;

ADRENAL METASTASIS; ADULT; AGED; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHILD PUGH SCORE; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; FOLLOW UP; HAND FOOT SYNDROME; HEPATITIS B VIRUS; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER RESECTION; LUNG METASTASIS; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; OPERATIVE BLOOD LOSS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; RETROSPECTIVE STUDY; SKIN MANIFESTATION; SPINE METASTASIS; SURVIVAL TIME; TUMOR THROMBUS; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; DISEASE COURSE; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; LIVER FUNCTION TEST; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; PATHOLOGY; RISK FACTOR; SECONDARY; TIME FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADMINISTRATION, ORAL; ADULT; CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; HEPATECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84963594611     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i15.4034     Document Type: Article

References (40)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]
2. Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol 1997; 12: S294-S308 [PMID: 9407350 DOI: 10.1111/j.1440-1746.1997.tb00513.x]
3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917 [PMID: 14667750 DOI: 10.1016/S0140-6736(03)14964-1]
4. Chiaramonte M, Stroffolini T, Vian A, Stazi MA, Floreani A, Lorenzoni U, Lobello S, Farinati F, Naccarato R. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999; 85: 2132-2137 [PMID: 10326690]
5. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338 [PMID: 10518312 DOI: 10.1055/s-2007-1007122]
6. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022 [PMID: 21374666 DOI: 10.1002/hep.24199]
7. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, Hung CH, Chen CH, Changchien CS, Hsu HC, Hu TH, Lee CM, Wang JH. Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. Eur J Cancer 2010; 46: 744-751 [PMID: 20060710 DOI: 10.1016/j.ejca.2009.12.018]
8. Cammà C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, Andreone P, Craxì A, Cottone M. Transarterial chemo-embolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002; 224: 47-54 [PMID: 12091661 DOI: 10.1148/radiol.2241011262]
9. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-442 [PMID: 12540794 DOI: 10.1053/jhep.2003.50047]
10. Lencioni R. Chemoembolization in patients with hepatocellular carcinoma. Liver Cancer 2012; 1: 41-50 [PMID: 24159570 DOI: 10.1159/000339019]
11. Colombo M, Sangiovanni A. Treatment of hepatocellular carcinoma: beyond international guidelines. Liver Int 2015; 35 Suppl 1: 129-138 [PMID: 25529098 DOI: 10.1111/liv.12713]
12. Ye JZ, Zhang YQ, Ye HH, Bai T, Ma L, Xiang BD, Li LQ. Appropriate treatment strategies improve survival of hepatocellular carcinoma patients with portal vein tumor thrombus. World J Gastroenterol 2014; 20: 17141-17147 [PMID: 25493028 DOI: 10.3748/wjg.v20.i45.17141]
13. Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, Girardi L, Cillo U, Burra P, Giacomin A, Farinati F. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 2008; 103: 914-921 [PMID: 18177453 DOI: 10.1111/j.1572-0241.2007.01712.x]
14. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430 [PMID: 11592607 DOI: 10.1016/S0168-8278(01)00130-1]
15. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236 [PMID: 16250051 DOI: 10.1002/hep.20933]
16. Jeng WJ, Lin CC, Chen WT, Sheen IS, Lin CY, Lin SM. Adjuvant therapy for hepatocellular carcinoma after curative treatment. Dig Dis 2014; 32: 747-754 [PMID: 25376293 DOI: 10.1159/000368017]
17. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Effcacy and safety of sorafenib in patients in the Asia-pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34 [PMID: 19095497 DOI: 10.1016/S1470-2045(08)70285-7]
18. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857]
19. Tai WT, Cheng AL, Shiau CW, Huang Hp, Huang JW, Chen pJ, Chen KF. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J Hepatol 2011; 55: 1041-1048 [PMID: 21354226 DOI: 10.1016/j.jhep.2011.01.047]
20. Wang JH, Changchien CS, Hu TH, Lee CM, Kee KM, Lin CY, Chen CL, Chen T Y, Huang YJ, Lu SN. The effcacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma-Survival analysis of 3892 patients. Eur J Cancer 2008; 44: 1000-1006 [PMID: 18337087 DOI: 10.1016/j.ejca.2008.02.018]
21. Changchien CS, Chen CL, Yen YH, Wang JH, Hu TH, Lee CM, Wang CC, Cheng YF, Huang YJ, Lin CY, Lu SN. Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival. J Gastroenterol 2008; 43: 159-170 [PMID: 18306990 DOI: 10.1007/s00535-007-2134-9]
22. Yang T, Lin C, Zhai J, Shi S, Zhu M, Zhu N, Lu JH, Yang GS, Wu MC. Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer (BCLC) staging. J Cancer Res Clin Oncol 2012; 138: 1121-1129 [PMID: 22402598 DOI: 10.1007/s00432-012-1188-0]
23. Zhong JH, Ke Y, Gong WF, Xiang BD, Ma L, Ye XP, Peng T, Xie GS, Li LQ. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann Surg 2014; 260: 329-340 [PMID: 24096763 DOI: 10.1097/SLA.0000000000000236]
24. Strasberg SM, Phillips C. Use and dissemination of the brisbane 2000 nomenclature of liver anatomy and resections. Ann Surg 2013; 257: 377-382 [PMID: 22895397 DOI: 10.1097/SLA.0b013e31825a01f6]
25. Kudo M. Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. Liver Cancer 2012; 1: 62-70 [PMID: 24159574 DOI: 10.1159/000342402]
26. Lin S, Hoffmann K, Schemmer P. Treatment of hepatocellular carcinoma: a systematic review. Liver Cancer 2012; 1: 144-158 [PMID: 24159579 DOI: 10.1159/000343828]
27. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007; 27: 55-76 [PMID: 17295177 DOI: 10.1055/s-2006-960171]
28. Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J Hepatol 2004; 41: 864-880 [PMID: 15519663 DOI: 10.1016/j.jhep.2004.09.006]
29. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66: 11851-11858 [PMID: 17178882 DOI: 10.1158/0008-5472. CAN-06-1377]
30. Arizumi T, Ueshima K, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M. Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Dig Dis 2014; 32: 705-710 [PMID: 25376287 DOI: 10.1159/000368006]
31. Wang JH, Kuo YH, Wang CC, Chen CL, Cheng YF, Hsu HC, Lu SN. Surgical resection improves the survival of selected hepatocellular carcinoma patients in Barcelona clinic liver cancer stage C. Dig Liver Dis 2013; 45: 510-515 [PMID: 23218990 DOI: 10.1016/j.dld.2012.10.019]
32. Bolondi L, Craxi A, Trevisani F, Daniele B, Di Costanzo GG, Fagiuoli S, Cammà C, Bruzzi p, Danesi R, Spandonaro F, Boni C, Santoro A, Colombo M. Refining sorafenib therapy: lessons from clinical practice. Future Oncol 2015; 11: 449-465 [PMID: 25360997 DOI: 10.2217/fon.14.261]
33. Zhang W, Zhao G, Wei K, Zhang Q, Ma W, Song T, Wu Q, Zhang T, Kong D, Li Q. Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: a single-center experience. Biosci Trends 2014; 8: 333-338 [PMID: 25641180 DOI: 10.5582/bst.2014.01120]
34. Kudo M. Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma. Dig Dis 2011; 29: 289-302 [PMID: 21829020 DOI: 10.1159/000327562]
35. Zhu AX. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer 2008; 112: 250-259 [PMID: 18041064 DOI: 10.1002/cncr.23175]
36. Nagai T, Arao T, Furuta K, Sakai K, Kudo K, Kaneda H, Tamura D, Aomatsu K, Kimura H, Fujita Y, Matsumoto K, Saijo N, Kudo M, Nishio K. Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma. Mol Cancer Ther 2011; 10: 169-177 [PMID: 21220499 DOI: 10.1158/1535-7163.MCT-10-0544]
37. Zhang CZ, Wang XD, Wang HW, Cai Y, Chao LQ. Sorafenib inhibits liver cancer growth by decreasing mTOR, AKT, and pI3K expression. J BUON 2015; 20: 218-222 [PMID: 25778319]
38. Rodríguez-Perálvarez M, Luong T V, Andreana L, Meyer T, Dhillon AP, Burroughs AK. A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. Ann Surg Oncol 2013; 20: 325-339 [PMID: 23149850 DOI: 10.1245/s10434-012-2513-1]
39. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699 [PMID: 7560864 DOI: 10.1016/0168-8278(95)80226-6]
40. Japan Liver Cancer Study Group. Classification of primary liver cancer. 1st ed. Tokyo: Kanehara & Co, 1997